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Vitamin D Deﬁciency Is Not Good for You
I
n this issue of Diabetes Care, Joergensen
et al. (1) demonstrate a strong associa-
tion between severe vitamin D deﬁ-
ciency and increased mortality in patients
with type 1 diabetes. This observation
conﬁrms previous ﬁndings in the general
population and in subgroups at high car-
diovascular risk such as patients with
type 2 diabetes or renal impaired patients
(2–4). The data by Joergensen et al. com-
plete the picture while carefully avoiding
possible criticisms that have made the
vitamin D ﬁeld so hazardous to tread in
recent years. Indeed, rather than hard sci-
ence,it is hype andmedia statementsthat
crowd the scene. This article brings with
i tab r e a t ho ff r e s ha i r .
Many studies are conducted retro-
spectively or measure vitamin D levels
when patients are already sick. Thanks to
the excellent registries present in several
Northern European countries—and here
in particular thanks to the database and
tissue bank of the reputed Steno Diabetes
Center—this study is able to assess levels
of vitamin D measured within 3 years af-
ter diagnosis and during up to 25 years of
clinical follow-up. This way of working
avoids justiﬁed criticisms on studies
where vitamin D levels were measured
at the time of severe diseases. Obviously,
patients with congestive heart failure or
cancer are less likely to go out and about
in the sun or eat fatty ﬁsh. Only prospec-
tive studies will help to understand the
relationship between vitamin D levels
anddisease.Because vitaminDdeﬁciency
in rodents in the early stages of life is
predictive of future disease, it would be
of great interest to evaluate vitamin D
levels in neonates. We have previously
demonstrated a twofold risk for the de-
velopment of diabetes in NOD mice that
had been vitamin D deﬁcient in the ﬁrst
100 days of their lives (5). As vitamin D
levels can be measured on dried spots of
blood of Guthrie cards that are routinely
obtained from all newborns in many
countries, such a study is both feasible
and could potentially further elucidate
the link between vitamin D levels and
the development of a wide range of dis-
eases.
The choice of measuring vitamin D
levels using the gold standard method
of liquid chromatography followed by
tandem mass spectrometry (LC/MS-MS)
is a second asset of the present work (6).
Although levels of 25-hydroxyvitamin D
[25(OH)D] are high enough to allow de-
tection by immunoassay techniques,
avoiding the use of antibodies results in
much more reliable measurements with
LC/MS-MS. Furthermore, novel data in-
dicate that modiﬁed forms of 25(OH)D
may be circulating that are falsely over-
detectedornotdetectedbytheantibodies
and may have physiological implications.
Still, at present only a few laboratories
around the world are able to measure
25(OH)D byLC/MS-MS,andmostlabora-
tories therefore continue to use kits. Their
continued widespread use might lead to
an overestimation of both the frequency
and magnitude of vitamin D deﬁciency.
This brings us to the other crucial
question of where to put the cutoff that
deﬁnes vitamin D deﬁciency, even with
LC/MS-MS. We do not know, and we do
nothaveaconsensus.Inaddition,thereis
ongoing debate concerning the dosage of
nutritional and vitamin D supplements
required to achieve vitamin D sufﬁciency
(7). The turmoil around a statement re-
leased by the Institute of Medicine (IOM)
is just an illustration of the problem. For
bone health, deﬁning the level of vitamin
Dd e ﬁciency is relatively easy as the rise
in parathyroid hormone levels can be
used as a marker for vitamin D levels that
are too low. When 25(OH)D levels drop
below 10–20 ng/mL (25–50 nmol/L),
parathyroid hormone levels rise, indicat-
ing the switching on of the feedback cas-
cade, suggesting that this is the level
below which 25(OH)D levels are really
deﬁcient. Here, the authors avoid the cut-
off discussion and its clinical relevance
by using the lower 10th percentile to de-
ﬁne deﬁciency. As a consequence, this
study’s conclusion is based on data from
very severely vitamin D–deﬁcient individ-
uals. Literature on the effects of vitamin D
at levels above 20 ng/mL (50 nmol/L) be-
comes very difﬁcult to interpret because
t h eo n l ya v a i l a b l ed a t aa r ef r o ma s s o -
ciation or preclinical studies in animal
models.
So, what should we conclude with
regard to vitamin D deﬁciency (and here
we agree to talk about the true deﬁciency,
t h es e v e r eo n e ) ?T h eN a t i o n a lH e a l t h
and Nutrition Examination Survey
(NHANES) indicated a continuum on
mortality risk in the general population
with an increased cardiovascular risk in
patients with low vitamin D levels. In
diseases like type 2 diabetes and chronic
renal failure, similar observations were
made,suggestingthattheexcessmortality
is related to an increase in cardiovascular
events. This hypothesis is strengthened
by preclinical and in vitro data. Higher
levelsofinﬂammation,higherbloodpres-
sure, and increased vascular resistance (via
renin-angiotensin-aldosteronesystem)are
observed in vitamin D–deﬁcient patients
andanimals,whereassupplementingwith
regular vitamin D or activated forms of
vitamin D (native 1,25-dihydroxyvitamin
D or a synthetic analog such as paricalci-
tol) lowers inﬂammation, lowers blood
pressure, and decreases vascular resis-
tance (8). Interestingly, the current study
did not ﬁnd an association between vita-
minDdeﬁciencyandtheonsetorprogres-
sion of nephropathy, whereas in previous
studies in patients with type 2 diabetes
a n di nm o d e l so fc h r o n i cr e n a li m p a i r -
ment, vitamin D deﬁciency is associated
with microalbuminuria and supplement-
ingwithvitaminD(analogs)preventspro-
gression to proteinuria (9). This ﬁnding
suggests that the pathogenesis of mi-
croalbuminuria in type 1 diabetes is a
completely different entity from microal-
buminuria in type 2 diabetes or other
forms of renal disease. In type 1 diabetes,
nephropathy is probably purely microan-
giopathic and therefore closely related to
the development of retinopathy, both of
which were uninﬂuenced by vitamin D
status here.
In view of the mean age and the sur-
vival curves of the patients, it is question-
able that cardiovascular events contribute
signiﬁcantly to mortality in this study. As
we have no insight into the direct causes
ofdeath,othereventssuchasaccidentsor
cancer may underlie the increased mor-
tality in vitamin D–deﬁcient patients
with type 1 diabetes. Accidents are hard
to account for by vitamin D deﬁciency,
but an increased cancer risk does come
out of other epidemiological studies
(10). Almost all cancers are correlated
with vitamin D deﬁciency (with the cau-
tion that in most studies, vitamin D is
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EDITORIAL (SEE JOERGENSEN ET AL., P. 1081 )dosed when cancer is already present),
exceptforpancreaticcancerwhereseveral
studiespointtoalowerriskinindividuals
with lower vitamin D levels (11,12).
What should we do now? Evidence
linking true vitamin D deﬁciency (,10
ng/mL [25 nmol/L]) to adverse outcomes
seemssolid,andtheimpactofthevitamin
Dd e ﬁciency happens early in life. Avoid-
ing vitamin D deﬁciency is thus the
message. The IOM has conﬁrmed the nu-
tritional advice that existed: 600 IU of vi-
taminDperdayassupplementsorinfood
(fortiﬁed products, or fatty ﬁsh like
mackerel...:) for all and 800 IU for peo-
p l eo v e r7 0y e a r so fa g e( 7 ) .O n em a yo f
course also makehisorherown bysitting
in the sun. Half an hour of exposure of
face and hands daily should sufﬁce to
maintain adequate vitamin D levels, but
some caveats apply (13). The wavelength
of UV light that is necessary to make vita-
min D in skin is exactly the same as the
one that ages skin and causes skin cancer.
Moreover, in winter, the sun does not rise
highenoughintheskyinlargepartsofthe
U.S., Europe, and certainly Canada, to
allow us to make any vitamin D. And if
one is dark skinned, exposing skin to sun
has almost no effect on vitamin D levels.
Exciting data point toward an “individ-
ual” set point for vitamin D sufﬁciency
determined by the presence of polymor-
phisms in the carrier protein (DBP), but
also polymorphisms in the vitamin D
receptor and the enzyme responsible for
ﬁnal activation of vitamin D into 1,25-
dihydroxyvitamin D (CYP27B1). This
implies one individual may have to take
more vitamin D in order to achieve vita-
min D sufﬁciency than another (14).
Inthisstudy,norelationshipbetween
BMI and vitamin D levels was observed
despite overwhelming evidence that a
negative correlation exists (15). The rea-
son is that these young Danes were all of
normal weight (mean BMI 20 kg/m
2). In
overweight patients, vitamin D accu-
mulates in excess fat, leading to low cir-
culating levels. Therefore, doctors should
certainly screen for vitamin D deﬁciency
in obese patients with diabetes and re-
plete if necessary. Extra attention should
be paid to patients who underwent bar-
iatric surgery causing fat malabsorption.
These individuals are at extreme risk of
vitamin D deﬁciency and sometimes
needextremedosestoachievesufﬁciency
(16).
In conclusion, vitamin D deﬁciency
is associated with increased mortality in
type 1 diabetic patients as well. Being
awareofpopulationsatriskandscreening
for vitamin D deﬁciency with appropriate
methods is therefore essential. Cutoff
levels for deﬁciency and sufﬁciency are
under discussion, but levels below 10
ng/mL (25 nmol/L) are considered se-
verely deﬁcient and should certainly be
avoided and supplemented. Guidelines
suggest supplements of vitamin D of
600 IU per day in all and 800 IU in
elderly (age .70 years). Many voices
shout for higher doses, but only demon-
strating these claims by hard clinical data
will move the ﬁeld forward from hype to
science.
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